Table 3.
Multivariable analysis for early NRM, NRM, REL.
| NRM day 100 | NRM day 180 | NRM | REL | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | ||
| TCI | Low (Ref) | 1 | 1 | 1 | 1 | ||||
| Intermediate | 1.95 (1.42–2.69) | <0.0001 | 1.62 (1.26–2.08) | 0.0001 | 1.44 (1.20–1.74) | 0.0001 | 0.66 (0.57–0.78) | <0.0001 | |
| High | 4.00 (2.20–7.28) | <0.0001 | 2.86 (1.76–4.64) | <0.0001 | 1.87 (1.25–2.80) | 0.003 | 0.79 (0.55–1.13) | 0.20 | |
| High vs Intermed. | 2.05 (1.17–3.57) | 0.012 | 1.76 (1.12–2.78) | 0.015 | 1.3 (0.88–1.91) | 0.19 | 1.19 (0.83–1.7) | 0.34 | |
| Age | per 10 years | 1.76 (1.31–2.37) | 0.0002 | 1.66 (1.31–2.11) | <0.0001 | 1.65 (1.38–1.97) | <0.0001 | 0.95 (0.82–1.11) | 0.53 |
| HCT-CI | 0 (Ref) | 1 | 1 | 1 | 1 | ||||
| 1–2 | 1.15 (0.81–1.62) | 0.43 | 1.07 (0.82–1.42) | 0.61 | 1.33 (1.09–1.62) | 0.006 | 0.99 (0.83–1.18) | 0.94 | |
| ≥3 | 1.49 (1.07–2.09) | 0.019 | 1.41 (1.08–1.83) | 0.011 | 1.38 (1.12–1.69) | 0.002 | 1.05 (0.88–1.24) | 0.59 | |
| KPS | ≤80 | 1.65 (1.23–2.21) | 0.0008 | 1.53 (1.22–1.94) | 0.0003 | 1.46 (1.22–1.75) | <0.0001 | 1.02 (0.87–1.2) | 0.77 |
| Year of HCT | 0.94 (0.82–1.07) | 0.31 | 0.96 (0.87–1.07) | 0.49 | 1.06 (0.97–1.15) | 0.20 | 1.08 (1–1.16) | 0.045 | |
| Sec AML | Yes vs. no | 0.91 (0.64–1.29) | 0.59 | 1.03 (0.79–1.35) | 0.81 | 1.14 (0.94–1.39) | 0.18 | 1.19 (1–1.41) | 0.054 |
| Cytogenetics | Favorable (Ref) | 1 | 1 | 1 | 1 | ||||
| Intermediate | 3.42 (0.84–13.96) | 0.087 | 3.67 (1.17–11.54) | 0.026 | 1.89 (1.00–3.56) | 0.051 | 0.97 (0.63–1.5) | 0.89 | |
| Adverse | 3.69 (0.89–15.32) | 0.072 | 4.14 (1.3–13.2) | 0.016 | 2.24 (1.17–4.29) | 0.015 | 2.10 (1.35–3.26) | 0.001 | |
| NA/failed | 4.65 (1.09–19.94) | 0.038 | 5.30 (1.62–17.3) | 0.006 | 2.46 (1.25–4.85) | 0.009 | 1.42 (0.88–2.28) | 0.15 | |
| Donor | UD vs. MSD | 1.51 (1.04–2.19) | 0.031 | 1.34 (1–1.79) | 0.047 | 1.23 (1–1.53) | 0.054 | 0.92 (0.77–1.09) | 0.33 |
| Sex | Female to Male | 1.12 (0.78–1.61) | 0.52 | 1.18 (0.89–1.57) | 0.25 | 1.36 (1.11–1.66) | 0.003 | 0.88 (0.72–1.07) | 0.21 |
| Graft source | PB vs. BM | 1.38 (0.6–3.17) | 0.44 | 1.08 (0.6–1.95) | 0.80 | 0.80 (0.53–1.2) | 0.28 | 0.64 (0.47–0.89) | 0.007 |
| In vivo TCD | Yes vs. No | 1.17 (0.8–1.71) | 0.41 | 1.20 (0.9–1.61) | 0.22 | 1.13 (0.91–1.41) | 0.26 | 1.14 (0.96–1.37) | 0.13 |
| Patient CMV | Pos vs. Neg | 1.26 (0.91–1.75) | 0.17 | 1.17 (0.9–1.53) | 0.23 | 1.14 (0.94–1.39) | 0.18 | 1.12 (0.95–1.32) | 0.19 |
| Donor CMV | Pos vs. Neg | 0.77 (0.57–1.02) | 0.066 | 0.91 (0.73–1.15) | 0.44 | 0.95 (0.80–1.13) | 0.59 | 1.06 (0.91–1.23) | 0.43 |
N = 3791 complete cases. Cox regression models included a frailty term for center. Results are expressed as hazard ratio (HR) with 95% confidence interval (CI). Bold denotes statistically significant.